Table 2. Characteristics of the ALK+ and EGFR+ NSCLC patients included in Figure 3.
| ALK+ patients | ALK+ NSCLC | EGFR+ NSCLC TKI-treated, (n = 344)3 |
|||
|---|---|---|---|---|---|
| >1 TKI, (n = 74) | 1 TKI, (n = 109) | ||||
| Age (median; IQR) | 51; 14 | 59; 11 | 65; 12 | ||
| Never/light-smokers (<10 py), n (%) 1 | 44/50 (88%) | 53/78 (68%) | 154/341 (45%) | ||
| ECOG PS (median; IQR) 1 | 0; 1 | 0; 1 | 1;1 | ||
| TKI treatment, n (%) | crizotinib | 72 (97%) | 92 (85%) | erlotinib | 183 (53%) |
| ceritinib | 50 (68%) | 7 (6%) | gefitinib | 79 (23%) | |
| alectinib | 46 (62%) | 8 (7%) | afatinib | 117 (34%) | |
| brigatinib | 14 (19%) | 2 (2%) | osimertinib | 61 (18%) | |
| lorlatinib | 6 (8%) | - | |||
| Summary of the complete treatment | |||||
| no. of TKI treatment lines (mean; SD) | 2.6; 0.8 | 1.0; 0.0 | 1.3; 0.6 | ||
| no. of treatment lines for St. IV (mean; SD) | 4.2; 1.6 | 2.3; 1.6 | 2.2; 1.3 | ||
| patients with additional radiotherapy (%) | 43 (58%) | 48 (44%) | 176 (51%) | ||
| patients with additional surgical treatment 2 | 9 (12%) | 10 (9%) | 25 (7%) | ||
1 Data not available for all patients.
2 Excluding video-assisted thoracoscopy for pleural effusion.
3 Most patients were treated before availability of osimertinib, and some received more than one EGFR inhibitors, due to poor tolerability of the first compound or in different treatment lines alternating with chemotherapy.
Abbreviations: IQR: interquartile range; py: pack-years; PS: performance status; TKI: tyrosine kinase inhibitors; SD: standard deviation; no.: number.